SBRT for oligoprogressive disease: using the evidence to maximise the benefits

Gerard G. Hanna; Fiona McDonald

doi:10.1016/S0140-6736(23)02351-6

SBRT for oligoprogressive disease: using the evidence to maximise the benefits

Gerard G. Hanna^*, Fiona McDonald

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

3 Citations (Scopus)

Original language	English
Pages (from-to)	122-124
Number of pages	3
Journal	The Lancet
Volume	403
Issue number	10422
Early online date	11 Jan 2024
DOIs	https://doi.org/10.1016/S0140-6736(23)02351-6
Publication status	Published - 13 Jan 2024

Keywords

SBRT
oligometastatic
lung cancer
breast cancer
Stereotactic
SABR

ASJC Scopus subject areas

General Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(23)02351-6Licence: Unspecified

Cite this

@article{735255775cf84c2fad5904b382c6fb08,

title = "SBRT for oligoprogressive disease: using the evidence to maximise the benefits",

keywords = "SBRT, oligometastatic, lung cancer, breast cancer, Stereotactic, SABR",

author = "Hanna, {Gerard G.} and Fiona McDonald",

year = "2024",

month = jan,

day = "13",

doi = "10.1016/S0140-6736(23)02351-6",

language = "English",

volume = "403",

pages = "122--124",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier B.V.",

number = "10422",

}

TY - JOUR

T1 - SBRT for oligoprogressive disease: using the evidence to maximise the benefits

AU - Hanna, Gerard G.

AU - McDonald, Fiona

PY - 2024/1/13

Y1 - 2024/1/13

KW - SBRT

KW - oligometastatic

KW - lung cancer

KW - breast cancer

KW - Stereotactic

KW - SABR

U2 - 10.1016/S0140-6736(23)02351-6

DO - 10.1016/S0140-6736(23)02351-6

M3 - Comment/debate

C2 - 38104574

AN - SCOPUS:85180294255

SN - 0140-6736

VL - 403

SP - 122

EP - 124

JO - The Lancet

JF - The Lancet

IS - 10422

ER -